Subsequently, we analyzed the relationship between the engraftment rate and some tumor biomarkers, including serum tumor markers (AFP, carcinoembryonic antigen (CEA), cancer antigen 199 (CA199), and cancer antigen 125 (CA125)), immunohistochemical markers (Ki-67, HER-2, and MMR status), as well as the mutational status of RAS and BRAF genes, and molecular therapeutic targets of colon cancer. This evidence concerns the gene ERBB2 and neoplasm.